Synlogic Provides Corporate Update and Outlook for 2024
January 04, 2024 07:00 ET
|
Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
December 14, 2023 07:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3...
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
December 07, 2023 07:00 ET
|
Synlogic, Inc.
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE...
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
October 03, 2023 16:15 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
August 24, 2023 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase,...
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
June 08, 2023 06:45 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will...
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 29, 2023 06:40 ET
|
Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 20, 2023 06:55 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
March 07, 2023 06:57 ET
|
Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Synlogic Provides Corporate Update and Outlook for 2023
January 05, 2023 06:58 ET
|
Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...